JP2020530989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530989A5 JP2020530989A5 JP2020503988A JP2020503988A JP2020530989A5 JP 2020530989 A5 JP2020530989 A5 JP 2020530989A5 JP 2020503988 A JP2020503988 A JP 2020503988A JP 2020503988 A JP2020503988 A JP 2020503988A JP 2020530989 A5 JP2020530989 A5 JP 2020530989A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- cell
- car
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023117421A JP2023134735A (ja) | 2017-07-25 | 2023-07-19 | 強化されたキメラ抗原受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762536934P | 2017-07-25 | 2017-07-25 | |
| US62/536,934 | 2017-07-25 | ||
| PCT/US2018/043779 WO2019023396A1 (en) | 2017-07-25 | 2018-07-25 | ENHANCED CHIMERIC ANTIGENIC RECEPTORS AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023117421A Division JP2023134735A (ja) | 2017-07-25 | 2023-07-19 | 強化されたキメラ抗原受容体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530989A JP2020530989A (ja) | 2020-11-05 |
| JP2020530989A5 true JP2020530989A5 (enExample) | 2021-09-02 |
Family
ID=65040821
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503988A Withdrawn JP2020530989A (ja) | 2017-07-25 | 2018-07-25 | 強化されたキメラ抗原受容体およびその使用 |
| JP2023117421A Pending JP2023134735A (ja) | 2017-07-25 | 2023-07-19 | 強化されたキメラ抗原受容体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023117421A Pending JP2023134735A (ja) | 2017-07-25 | 2023-07-19 | 強化されたキメラ抗原受容体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240336699A1 (enExample) |
| EP (2) | EP4582146A2 (enExample) |
| JP (2) | JP2020530989A (enExample) |
| KR (1) | KR20200032174A (enExample) |
| CN (2) | CN118206655A (enExample) |
| AU (1) | AU2018306307B2 (enExample) |
| CA (1) | CA3070998A1 (enExample) |
| TW (1) | TW201908335A (enExample) |
| WO (1) | WO2019023396A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020106621A1 (en) * | 2018-11-19 | 2020-05-28 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
| WO2021032783A1 (en) | 2019-08-21 | 2021-02-25 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Methods for detecting, quantifying and monitoring immune-cell mediated cytotoxicity of cell populations comprising immune cells and/or stem cells |
| NL2023924B1 (nl) * | 2019-10-01 | 2021-06-01 | Lely Patent Nv | Meetsysteem voor levensmiddelen |
| CN115461361B (zh) * | 2020-05-08 | 2025-03-14 | 玛希敦大学 | 嵌合抗原受体和携带该受体的经修饰的细胞 |
| KR102297396B1 (ko) * | 2020-07-29 | 2021-09-06 | (주)티카로스 | 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포 |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| CN116981685A (zh) * | 2020-12-03 | 2023-10-31 | 世纪治疗股份有限公司 | 基因工程化细胞及其用途 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| CN113045658B (zh) | 2020-12-11 | 2021-12-24 | 广州百暨基因科技有限公司 | 抗cll1抗体及其应用 |
| CN113234169B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
| CA3210702A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Gene transfer vectors and methods of engineering cells |
| JP2024519515A (ja) | 2021-04-07 | 2024-05-15 | センチュリー セラピューティクス，インコーポレイテッド | 人工多能性幹細胞からガンマ－デルタｔ細胞を生成するための組成物および方法 |
| CN117441010A (zh) | 2021-04-07 | 2024-01-23 | 世纪治疗股份有限公司 | 从诱导多能干细胞产生α-βT细胞的组合物和方法 |
| BR112023021133A2 (pt) * | 2021-04-14 | 2023-12-12 | Univ Texas | Receptores quiméricos de antígenos para direcionar cânceres positivos para cd5 |
| AR127745A1 (es) * | 2021-10-18 | 2024-02-28 | Kite Pharma Inc | Dominios de señalización para receptores quiméricos de antígenos |
| EP4456912A1 (en) | 2021-12-29 | 2024-11-06 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
| US20250090582A1 (en) | 2022-06-08 | 2025-03-20 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof |
| WO2023240169A1 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof |
| WO2024102838A1 (en) | 2022-11-09 | 2024-05-16 | Century Therapeutics, Inc. | Engineered interleukin-7 receptors and uses thereof |
| WO2024103017A2 (en) | 2022-11-10 | 2024-05-16 | Century Therapeutics, Inc. | Genetically engineered cells having anti-nectin4 chimeric antigen receptors, and uses thereof |
| WO2024240243A1 (en) * | 2023-05-25 | 2024-11-28 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors and uses thereof |
| WO2025101938A2 (en) | 2023-11-10 | 2025-05-15 | Century Therapeutics, Inc. | Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof |
| WO2025106626A1 (en) | 2023-11-15 | 2025-05-22 | Century Therapeutics, Inc. | Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof |
| WO2025207798A1 (en) | 2024-03-26 | 2025-10-02 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof |
| WO2025207795A1 (en) | 2024-03-26 | 2025-10-02 | Juno Therapeutics, Inc. | Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69233204T2 (de) * | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| ES2911246T3 (es) * | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| CA3133545C (en) * | 2012-05-25 | 2023-08-08 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| SG11201505896YA (en) * | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| KR102238226B1 (ko) * | 2013-05-14 | 2021-04-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| EP3925618A1 (en) * | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| KR20160145802A (ko) * | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| HK1243441A1 (zh) * | 2014-11-05 | 2018-07-13 | Board Of Regents, The University Of Texas System | 基因修饰的免疫效应细胞和用於扩增免疫效应细胞的工程化细胞 |
| CA2973529A1 (en) * | 2015-01-26 | 2016-08-04 | Cellectis | Cll1-specific multi-chain chimeric antigen receptor |
| US10786549B2 (en) * | 2015-04-23 | 2020-09-29 | Baylor College Of Medicine | CD5 chimeric antigen receptor for adoptive T cell therapy |
| WO2017096329A1 (en) * | 2015-12-03 | 2017-06-08 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
| WO2017112877A1 (en) * | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
-
2018
- 2018-07-25 TW TW107125720A patent/TW201908335A/zh unknown
- 2018-07-25 JP JP2020503988A patent/JP2020530989A/ja not_active Withdrawn
- 2018-07-25 CA CA3070998A patent/CA3070998A1/en active Pending
- 2018-07-25 CN CN202410061631.8A patent/CN118206655A/zh active Pending
- 2018-07-25 CN CN201880058794.3A patent/CN111432823A/zh active Pending
- 2018-07-25 KR KR1020207005375A patent/KR20200032174A/ko not_active Ceased
- 2018-07-25 EP EP25169707.4A patent/EP4582146A2/en active Pending
- 2018-07-25 AU AU2018306307A patent/AU2018306307B2/en active Active
- 2018-07-25 EP EP18838056.2A patent/EP3658163A4/en not_active Withdrawn
- 2018-07-25 WO PCT/US2018/043779 patent/WO2019023396A1/en not_active Ceased
-
2023
- 2023-07-19 JP JP2023117421A patent/JP2023134735A/ja active Pending
-
2024
- 2024-06-21 US US18/750,233 patent/US20240336699A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530989A5 (enExample) | ||
| JP7599205B2 (ja) | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 | |
| US20200038443A1 (en) | Multi-function and multi-targeting car system and methods for use thereof | |
| EP4400516A1 (en) | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 | |
| CN118546959A (zh) | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 | |
| CA3090546A1 (en) | Chimeric antigen receptors targeting the tumor microenvironment | |
| JP2020517259A5 (enExample) | ||
| CN108138148B (zh) | T细胞的激活和扩增 | |
| JP2015527070A5 (enExample) | ||
| WO2014165818A2 (en) | Compositions and methods for preventing and treating prostate cancer | |
| CN112638947A (zh) | 用于治疗实体瘤的嵌合抗原受体细胞 | |
| JP2021530971A (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| WO2018045034A1 (en) | Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain | |
| JP2024105603A (ja) | ＣＡＲライブラリおよびｓｃＦｖの製造方法 | |
| AU2021267893A1 (en) | Anti-tumor associated antigen antibodies and uses thereof | |
| Fine et al. | Mechanism-driven design of multispecific antibodies for targeted disease treatment | |
| WO2024173376A2 (en) | Combination therapy comprising multispecific gamma delta tcr antibodies | |
| AU2023234457A1 (en) | Anti-mesothelin antibodies and uses thereof | |
| US20210079111A1 (en) | Cd19-cd20 bispecific and dual passway car-t and methods for use thereof | |
| WO2025093035A1 (en) | Cd40-targetting antibodies and uses thereof | |
| US20250136703A1 (en) | Anti-il13ra2 antibodies and uses thereof | |
| JP2025538424A (ja) | 併用療法の投与レジメン | |
| WO2024076864A2 (en) | Anti-ror1 antibodies and uses thereof | |
| WO2024210072A1 (ja) | キメラタンパク質、核酸、ベクター、ｔ細胞又はｎｋ細胞、医薬組成物、組み合わせ物、組み合わせ医薬、及び標的抗原結合タンパク質 | |
| EP4615501A1 (en) | Anti-5t4 antibodies and uses thereof |